Valiollahi Ehsan, Ribera Josep Maria, Genescà Eulàlia, Behravan Javad
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Josep Carreras Research Institute (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Mol Biol Rep. 2019 Feb;46(1):1295-1306. doi: 10.1007/s11033-019-04600-5. Epub 2019 Feb 2.
Acute lymphoblastic leukemia (ALL) is a malignant transformation with uncontrolled proliferation of lymphoid precursor cells within bone marrow including a dismal prognosis after relapse. Survival of a population of quiescent leukemia stem cells (LSCs, also termed leukemia-initiating cells (LICs)) after treatment is one of the relapse reasons in Ph ALL patient. MicroRNAs (miRNAs) are known as highly conserved 19-24 nucleotides non-protein-coding small RNAs that regulate the expression of human genes. miRNAs are often involved in the tuning of hematopoiesis. Therefore, the deregulation of miRNA expression and function in hematopoietic cells can cause cancer and promote its progression. This is the first comprehensive analysis of miRNA expression differences between CD34CD38 LSCs and CD34CD38 leukemic progenitors (LPs) from the same Ph B-ALL bone marrow samples using high-throughput sequencing technologies. We identified multiple differentially expressed miRNAs including hsa-miR-3143, hsa-miR-6503-3p, hsa-miR-744-3p, hsa-miR-1226-3p, hsa-miR-10a-5p, hsa-miR-4658 and hsa-miR-493-3p related to LSC and LP populations which have regulatory functions in stem-cell associated biological processes. The deregulation of these miRNAs could affect leukemogenesis, clonogenic and stemness capacities in these subpopulations of Ph B-ALL. Therefore, identification of these LSC associated miRNAs may improve the diagnosis and management of B-ALL. These findings may also lead to future strategies to eliminate the presence of resistant LSCs, either by induction of apoptosis or by sensitizing these cells to chemotherapy.
急性淋巴细胞白血病(ALL)是一种骨髓内淋巴前体细胞恶性转化且增殖失控的疾病,复发后预后不佳。治疗后一群静止的白血病干细胞(LSCs,也称为白血病起始细胞(LICs))存活是Ph ALL患者复发的原因之一。微小RNA(miRNAs)是高度保守的19 - 24个核苷酸的非蛋白质编码小RNA,可调节人类基因的表达。miRNAs常参与造血调节。因此,造血细胞中miRNA表达和功能的失调可导致癌症并促进其进展。这是首次使用高通量测序技术对来自同一Ph B - ALL骨髓样本的CD34CD38 LSCs和CD34CD38白血病祖细胞(LPs)之间的miRNA表达差异进行全面分析。我们鉴定出多个差异表达的miRNAs,包括与LSC和LP群体相关的hsa - miR - 3143、hsa - miR - 6503 - 3p、hsa - miR - 744 - 3p、hsa - miR - 1226 - 3p、hsa - miR - 10a - 5p、hsa - miR - 4658和hsa - miR - 493 - 3p,它们在干细胞相关生物学过程中具有调节功能。这些miRNAs的失调可能影响Ph B - ALL这些亚群中的白血病发生、克隆形成和干性能力。因此,鉴定这些与LSC相关的miRNAs可能会改善B - ALL的诊断和管理。这些发现也可能导致未来消除耐药LSCs存在的策略,要么通过诱导细胞凋亡,要么通过使这些细胞对化疗敏感。